5 big analyst AI moves: Nvidia guidance warning; Snowflake, Palo Alto upgraded
Investing.com - Cantor Fitzgerald maintained its Neutral rating and $95.00 price target on LeMaitre Vascular (NASDAQ:LMAT), a $2.09 billion market cap medical device company, following its second-quarter 2025 financial results. According to InvestingPro data, the company maintains a "GREAT" financial health score, though it currently trades above its Fair Value.
LeMaitre reported revenue of $64.2 million for the quarter, exceeding both Cantor Fitzgerald’s estimate of $62.3 million and the FactSet consensus of $62.5 million. The results represented approximately 15% year-over-year growth, all of which was organic, continuing the company’s strong momentum with trailing twelve-month revenue growth of 14.11%. Six analysts have recently revised their earnings estimates upward for the upcoming period.
The company’s performance was driven by strong growth across product categories, with catheters increasing 27% year-over-year and grafts rising 19% compared to the same period last year.
Geographically, LeMaitre saw growth across all regions, with sales in the Americas up 12% year-over-year, EMEA (Europe, Middle East, and Africa) sales increasing 23%, and APAC (Asia-Pacific) sales growing 12%.
The medical device company also improved its gross margin, which increased 110 basis points to 70.0% in the second quarter, attributed to higher average selling prices and manufacturing efficiencies, according to Cantor Fitzgerald’s analysis.
In other recent news, LeMaitre Vascular Inc . reported impressive financial results for the second quarter of 2025. The company’s earnings per share (EPS) reached $0.60, surpassing analysts’ expectations of $0.57. This represents a 5.26% earnings surprise. Additionally, LeMaitre Vascular’s revenue for the quarter was $64.2 million, exceeding the projected $62.48 million by 2.75%. These financial results highlight the company’s strong performance during this period. The earnings and revenue figures are significant for investors, as they indicate better-than-expected financial health. These developments are crucial for stakeholders assessing the company’s recent performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.